Form 4: Arcus Biosciences CFO Robert Goeltz II Sells Shares Under 10b5-1 Trading Plan

Robert Goeltz II, CFO of Arcus Biosciences, sold 3,594 shares of common stock on December 31, 2024, at a price of $15 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Robert Goeltz II, the Chief Financial Officer of Arcus Biosciences, Inc. (RCUS), reported a transaction involving the sale of company stock.
• On December 31, 2024, Goeltz sold 3,594 shares of Arcus Biosciences common stock.
• The sale was executed at a price of $15 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2023.
• Following the transaction, Goeltz directly owns 60,138 shares of Arcus Biosciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The market typically views sales under 10b5-1 plans differently than discretionary sales.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The sale does not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates